Interim analysis based on the weighted log-rank test for delayed treatment effects under staggered patient entry

References

• Andersen, P. K., Gill, R. D. (1982). Cox’s regression model for counting processes: A large sample study. The Annals of Statistics 10:1100–1120.
   Web of Science ®Google Scholar
• Armitage, P., McPherson, C. K., Rowe, B. C. (1969). Repeated significance tests on accumulating data. Journal of the Royal Statistical Society, Series A 132:235–244.
   Web of Science ®Google Scholar
• Bilias, Y., Gu, M., Ying, Z. (1997). Towards a general asymptotic theory for Cox model with staggered entry. The Annals of Statistics 25:662–682.
   Web of Science ®Google Scholar
• Chow, S. C., Chang, M. (2007). Adaptive Design Methods in Clinical Trials. New York, NY: Chapman & Hall.
   Google Scholar
• Copier, J., Dalgleish, A. G., Britten, C. M., Finke, L. H., Gaudernack, G., Gnjatic, S., Kallen, K., Kiessling, R., Schuessler-Lenz, M., Singh, H., Talmadge, J. E., Zwierzina, H., Håkansson, L. (2009). Improving the efficacy of cancer immunotherapy. European Journal of Cancer 45:1424–1431.
   PubMed Web of Science ®Google Scholar
• Cytel, Inc. (2013). EAST User Manual, Version 6.2. Cambridge, MA: Cytel Inc.
   Google Scholar
• Davis, B. R., Hardy, R. J. (1990). Upper bounds for type I and type II error rates in conditional power calculations. Communications in Statistics–Theory and Methods 19:3571–3584.
   Web of Science ®Google Scholar
• Fine, G. D. (2007). Consequences of delayed treatment effects on analysis of time-to-event endpoints. Drug Information Journal 41:535–539.
   Web of Science ®Google Scholar
• Fleming, T. R., Harrington, D. P. (1991). Counting Process and Survival Analysis. Hoboken, NJ: John Wiley & Sons.
   Google Scholar
• Food and Drug Administration. (2011). Guidance for industry: Clinical considerations for therapeutic cancer vaccines. Available at http://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm278673.pdf (Accessed August 18, 2014).
   Google Scholar
• Halpern, J., Brown, B. W., Jr. (1987). Designing clinical trials with arbitrary specification of survival functions and for the log rank or generalized Wilcoxon test. Controlled Clinical Trials 8:177–189.
   PubMedGoogle Scholar
• Hoos, A., Eggermont, A. M., Janetzki, S., Hodi, F. S., Ibrahim, R., Anderson, A., Humphrey, R., Blumenstein, B., Old, L., Wolchok, J. (2010). Improved endpoints for cancer immunotherapy trials. Journal of the National Cancer Institute 102:1388–1397.
   PubMed Web of Science ®Google Scholar
• Jennison, C., Turnbull, B. W. (2000). Group Sequential Methods with Applications to Clinical Trials. New York, NY: Chapman & Hall.
   Google Scholar
• Kalbfleisch, J. D., Prentice, R. L. (2002). The Statistical Analysis of Failure Time Data. 2nd ed. Hoboken, NJ: John Wiley & Sons.
   Google Scholar
• Lachin, J. M. (2005). A review of methods for futility stopping based on conditional power. Statistics in Medicine 24:2747–2764.
   PubMed Web of Science ®Google Scholar
• Lan, K. K. G., Simon, R., Halperin, M. (1982). Stochastically curtailed tests in long-term clinical trials. Communications in Statistics–Sequential Analysis 1:207–219.
   Google Scholar
• Lan, K. K. G., DeMets, D. L. (1983). Discrete sequential boundaries for clinical trials. Biometrika 70:659–663.
   Web of Science ®Google Scholar
• Lan, K. K. G., Wittes, J. (1988). The B-value: A tool for monitoring data. Biometrics 44:579–585.
   PubMed Web of Science ®Google Scholar
• Lan, K. K. G., Zucker, D. M. (1993). Sequential monitoring of clinical trials: The role of information and Brownian motion. Statistics in Medicine 12:753–765.
   PubMed Web of Science ®Google Scholar
• Lan, K. K. G. (1994). Information and information fractions for design and sequential monitoring of clinical trials. Communications in Statistics–Theory and Methods 23:403–420.
   Web of Science ®Google Scholar
• Lin, D. Y., Yao, Q., Ying, Z. (1999). A general theory on stochastic curtailment for censored survival data. Journal of the American Statistical Association 94:510–521.
   Web of Science ®Google Scholar
• Loader, C. R. (1991). Inference for a hazard rate change point. Biometrika 78:749–757.
   Web of Science ®Google Scholar
• Muller, H. G., Wang, J. L. (1994). Change-point models for hazard functions. IMS Lecture Notes 23:224–241.
   Google Scholar
• SAS Institute, Inc. (2011). SAS/STAT User’s Guide, Version 9.3. Cary, NC: SAS Institute, Inc.
   Google Scholar
• Sellke, T., Siegmund, D. (1983). Sequential analysis of the proportional hazards model. Biometrika 70:315–326.
   Web of Science ®Google Scholar
• Slud, E., Wei, L. J. (1982). Two-sample repeated significance tests based on the modified Wilcoxon statistics. Journal of the American Statistical Association 77:862–868.
   Web of Science ®Google Scholar
• Spiegelhalter, D. J., Freedman, L. S., Blackburn, P. R. (1986). Monitoring clinical trials: Conditional or predictive power? Controlled Clinical Trials 7:8–17.
   PubMedGoogle Scholar
• Spiegelhalter, D. J., Freedman, L. S., Parmar, M. K. (1994). Bayesian approaches to randomized trials. Journal of the Royal Statistical Society, Series A 157:357–387.
   Web of Science ®Google Scholar
• Tsiatis, A. A. (1982). Repeated significance testing for a general class of statistics used in censored survival analysis. Journal of the American Statistical Association 77:855–861.
   Web of Science ®Google Scholar
• Worsley, K. J. (1988). Exact percentage points of the likelihood-ratio test for a change-point hazard-rate model. Biometrics 44:259–263.
   PubMed Web of Science ®Google Scholar